Randomized Dose-Ranging Study of the 14-Day Early Bactericidal Activity of Bedaquiline (TMC207) in Patients with Sputum Microscopy Smear-Positive Pulmonary Tuberculosis

Bedaquiline is a new antituberculosis agent targeting ATP synthase. This randomized, double-blinded study enrolling 68 sputum smear-positive pulmonary tuberculosis patients evaluated the 14-day early bactericidal activity of daily doses of 100 mg, 200 mg, 300 mg, and 400 mg bedaquiline, preceded by...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Diacon, Andreas H., Dawson, Rodney, Von Groote-Bidlingmaier, Florian, Symons, Gregory, Venter, Amour, Donald, Peter R., Conradie, Almari, Erondu, Ngozi, Ginsberg, Ann M., Egizi, Erica, Winter, Helen, Becker, Piet, Mendel, Carl M.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society for Microbiology 2013
Ämnen:
Clinical Therapeutics
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3632959/
https://ncbi.nlm.nih.gov/pubmed/23459487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02243-12
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk